Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet]

Susan L Norris; Susan Carson; Sujata Thakurta; Benjamin KS Chan

Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet]

Review

Portland (OR): Oregon Health & Science University; 2008 Aug.

Drug Class Reviews.

Authors

Susan L Norris¹, Susan Carson¹, Sujata Thakurta¹, Benjamin KS Chan¹

Affiliation

¹ Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director

PMID: 20496456
Bookshelf ID: NBK10739

Excerpt

There are 2 thiazolidinediones approved for prescription use in the United States, rosiglitazone maleate (Avandia^™) and pioglitazone hydrochloride (Actos^®). Both drugs are approved by the United States Food and Drug Administration for use in adults for the treatment of type 2 diabetes, either as monotherapy or in combination with insulin, metformin, or sulfonylurea when diet, exercise, and a single agent does not result in adequate glycemic control. Neither drug is currently approved for use in prediabetes or the metabolic syndrome. The objective of this review was to compare thiazolidinediones in the treatment of type 2 diabetes, prediabetes, and the metabolic syndrome.

Sections

Publication types

Review

Grants and funding

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.